PEPTIDE AND ANTICOAGULANT DRUGS MARKET SIZE & SHARE ANALYSIS - GROWTH TRENDS & FORECASTS (2023 - 2028)
North America is expected to hold a significant share of the peptide and anticoagulant drugs market throughout the forecast period due to the increasing necessity of drugs for cancer, increasing prevalence of cardiovascular disorders and other diseases, and high demand for peptide and anticoagulant drugs. The United States holds the largest market share in the North American region due to factors such as the increasing burden of cancer and the increasing prevalence of cardiovascular disorders, which is anticipated to stimulate the demand for peptide and anticoagulant drugs.
The rising prevalence of various cancer in the region is stimulating the market's growth. For instance, as per the Canada Cancer Society's statistics for 2022, around 6,700 Canadians were diagnosed with leukemia in 2021, out of which 4,000 were men and 2,700 were women. As per the American Cancer Society's data for 2023, around 59,610 new cases of leukemia and 20,380 new cases of acute myeloid leukemia (AML) are estimated to be diagnosed in the United States in 2023. Thus, the high incidence of cancer cases is leading to an increase in hemato oncology testing, thereby driving the market in the region.
The peptide and anticoagulant drugs market is projected to register a CAGR of 3.3% during the forecast period.
COVID-19 had a substantial impact on the market’s growth initially. For instance, according to an article published by Frontiers in May 2022, several peptide-based vaccine candidates and drug candidates were proposed during the pandemic, which positively affected the treatment of COVID-19 infections. Thus, the pandemic had a significant impact on the market’s growth. However, as the pandemic has subsided, the market is expected to have stable growth during the forecast period.
Factors such as the increasing prevalence of cancer and metabolic disorders, rising investments in the R&D of novel drugs, and technological advancements in drug development are expected to enhance the market’s growth.
According to an article published by the Heart and Stroke Foundation of Canada in February 2022, in Canada, 750,000 people were living with heart failure in 2022, and 100,000 people are diagnosed with this incurable condition each year. The source also stated that heart failure affects one in three Canadians, either because they have it themselves or because it affects a family member or close friend. Thus, the country's high burden of cardiovascular diseases is expected to boost the market’s growth.
Comments
Post a Comment